Judy will be responsible for all clinical and medical activities in the company, moving Arthex’ lead compound ATX-01 into clinical studies.
She started her career as a clinical neurologist and clinical trial investigator in Canada. In the late 1990s, Judy joined Quintiles (now IQVIA) in the US as Medical Director and head of a project management group working in the neurology space.
She then took on the role of Head of Neurology for ROW at Serono (Now Merck KgA) in Geneva, Switzerland. Later she became Head of Medical Affairs for Teva Neuroscience (Kansas City, MO) and then returned to Quintiles/IQVIA in 2008 as VP Strategic Drug Development group, based in the UK and was a member of the Rare Diseases Centre of Excellence. In April 2017, Judy was appointed Chief Medical Officer at Cerecin a US- Singapore biotech developing drugs for neurological disorders. As CMO and a member of Cerecin’s executive team, Judy was instrumental in securing funding for Cerecin’s next phase of growth, relocating the company strategic centre to Singapore, building a global drug development team, re-designing the clinical development programme, and establishing a regulatory strategyfor Cerecin’s lead drug.
Judy’s extensive experience and passion in Neurological Drug Development,
has prepared her for this new leadership role.